Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -1.6x - -1.7x | -1.7x |
| Selected Fwd P/E Multiple | -0.8x - -0.8x | -0.8x |
| Fair Value | €0.82 - €0.90 | €0.86 |
| Upside | 72.1% - 90.2% | 81.1% |
| Benchmarks | - | Full Ticker |
| Collegium Pharmaceutical, Inc. | - | NasdaqGS:COLL |
| Cumberland Pharmaceuticals Inc. | - | NasdaqGS:CPIX |
| Supernus Pharmaceuticals, Inc. | - | NasdaqGM:SUPN |
| Zevra Therapeutics, Inc. | - | NasdaqGS:ZVRA |
| Talphera, Inc. | - | NasdaqCM:TLPH |
| DURECT Corporation | - | DB:DC8A |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| COLL | CPIX | SUPN | ZVRA | TLPH | DC8A | |||
| NasdaqGS:COLL | NasdaqGS:CPIX | NasdaqGM:SUPN | NasdaqGS:ZVRA | NasdaqCM:TLPH | DB:DC8A | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | -8.2% | NM- | NM- | NM- | ||
| 3Y CAGR | -1.1% | NM- | 11.4% | NM- | NM- | NM- | ||
| Latest Twelve Months | -53.0% | 61.1% | 499.2% | -86.0% | 18.1% | 36.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 8.7% | -12.8% | 11.2% | -181.5% | -5990.5% | -461.4% | ||
| Prior Fiscal Year | 8.5% | -15.9% | 0.2% | -167.7% | -1580.2% | -1066.8% | ||
| Latest Fiscal Year | 11.0% | -17.1% | 11.2% | -446.9% | NA | -906.6% | ||
| Latest Twelve Months | 6.6% | -8.0% | 9.3% | -226.6% | -43392.6% | -801.5% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 5.0x | 26.4x | 11.8x | -10.5x | NA | -0.8x | ||
| Price / LTM Sales | 1.6x | 1.1x | 3.1x | 16.9x | 394.9x | 10.5x | ||
| LTM P/E Ratio | 23.8x | -13.7x | 33.5x | -7.4x | -0.9x | -1.3x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -13.7x | -0.9x | 33.5x | |||||
| Historical LTM P/E Ratio | -39.9x | -2.5x | -0.5x | |||||
| Selected P/E Multiple | -1.6x | -1.7x | -1.7x | |||||
| (x) LTM Net Income | (15) | (15) | (15) | |||||
| (=) Equity Value | 23 | 25 | 26 | |||||
| (/) Shares Outstanding | 25.5 | 25.5 | 25.5 | |||||
| Implied Value Range | 0.92 | 0.96 | 1.01 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.78 | 0.83 | 0.87 | 0.47 | ||||
| Upside / (Downside) | 65.4% | 74.1% | 82.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | COLL | CPIX | SUPN | ZVRA | TLPH | DC8A | |
| Value of Common Equity | 1,045 | 45 | 2,074 | 685 | 11 | 14 | |
| (/) Shares Outstanding | 32.1 | 15.0 | 62.6 | 54.7 | 20.5 | 25.5 | |
| Implied Stock Price | 32.52 | 3.00 | 33.12 | 12.53 | 0.52 | 0.55 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 32.52 | 3.00 | 33.12 | 12.53 | 0.52 | 0.47 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |